{"prompt": "['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', 'James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee', 'WM. Pharmacokinetics of Acetaminophen-Adduct in Adults with Acetaminophen', 'Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.', 'Jones, P., Harding, G., Berry, P., Wiklund, I., Chen, W-H., Leidy, N. Development and', 'first validation of the COPD Assessment Test (CAT) Eur Respir J, 2009; 34: 648-654', 'Jones, P., Harding, G., Wiklund, I., Berry, P., Tabberer, M., Yu, R., Leidy, N. Tests of', 'the Responsiveness of the Chronic Obstructive Pulmonary Disease (COPD) Assessment', 'Test (CAT) Following Acute Exacerbation and Pulmonary Rehabilitation Chest, 2012,', '142 134-140', 'Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, D\u00e9ny P, Gault E. Quantification', 'of Hepatitis Delta Virus RNA in Serum by Consensus Real-Time PCR Indicates', 'Different Patterns of Virological Response to Interferon Therapy in Chronically Infected', 'Patients. J Clin Microbiol. 2005;43(5):2363-2369.', 'Leidy NK, Sexton CC, Jones PW, Notte SM. et al. Measuring respiratory symptoms in', 'clinical trials of COPD: reliability and validity of a daily diary. Thorax 2014; 69:5 424-', '430', 'Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S. Standardizing', 'measurement of chronic obstructive pulmonary disease exacerbations. Reliability and', 'validity of a patient-reported diary. Am J Respir Crit Care Med 2011; 183:323-329', 'Mahler DA, Ward J, Fierro-Carrion G, et al. Development of self-administered versions', 'of modified baseline and transition dyspnea indexes in COPD. J COPD 2004; 165-172', 'Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea.', 'Contents, inter-observer agreement, and physiologic correlates of two new clinical', 'indexes. Chest 1984, 85: 751-758.', 'Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of', 'umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive', 'pulmonary disease: results of a 24-week, randomized, controlled trial. Respiratory', 'medicine. 014;108:1752-60.', 'Maltais F, Singh S, Donald AC, Crater G, Church A, Goh AH, Riley JH. Effects of a', 'combination of umeclidinium/vilanterol on exercise endurance in patients with chronic', 'obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv', 'Respir Dis. 2014;8:169-81.', 'Meguro M, Barley EA, Spencer S et al. Development and validation of an improved', 'COPD-Specific Version of the St. George Respiratory Questionnaire. Chest.', '2007;132:456-463', 'Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright', 'P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R,', '65']['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of', 'spirometry. Eur Respir J. 2005;26: 319-338.', 'Moy ML, Weston NA, Wilson EJ, Hess ML, Richardson CR. A pilot study of an Internet', 'walking program and pedometer in COPD. Respir Med. 2012;106:1342-50.', 'Quanjer P, Stanojevic S, Cole T, Baur X., Hall G, Enright P, et al. on behalf of the ERS', 'Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-', '95 year age range: the global lung function 2012 equations. Eur Respir J, 2012; 40:', '1324-1343.', 'Schmidt SA, Johansen MB, Olsen M et al. The impact of exacerbation frequency on', 'mortality following acute exacerbation of COPD: a registry-based cohort study. B Med J.', 'Open. 2014;4: (12): e006720', 'Serevent product information 2003. Available from', ' http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20236s1r028_serevent_lbl.pdf', 'Shu-Yi Liao, Roberto Benzo et al. Physical Activity Monitoring in Patients with Chronic', 'Obstructive Pulmonary Disease. Journal of the COPD Foundation 2014; 1: 155-165', 'Siler T, Kerwin E, Sousa A, Donald A, Rehan A, Church A, Efficacy and safety of', 'umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary', 'disease: Results of two randomized studies. Respir Med. 2015; 109:1155-63', 'Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. Prevention of', \"clinically important deteriorations in COPD with umeclidinium/vilanterol. Int'l J of\", 'COPD, 2016; 11:1413-1424', 'Tashkin DP, Fabbri LM. Long acting beta-agonists in the management of chronic', 'obstructive pulmonary disease: Current and future agents. Respir Research, 2010; 11:', '149', 'Trivedi R, Richard N, Mehta R, and Church, A. Umeclidinium in patients with COPD: a', 'randomised, placebo-controlled study. Eur Respir J. 2014; 43: 72-81.', 'Watz H, Waschki B, Meyer T, Magnussen H: Physical activity in patients with COPD.', 'Eur Respir J 2009, 33:262-272.', 'Wedzicha JA, Brill SE, Allinson JP, Donalson GC. Mechanism and impact of the', 'frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC', 'Medicine, 2013; 11:181', '66']\n\n###\n\n", "completion": "END"}